listed by broker
biotech / pharma
Founded in
Desired valuation:
open to offers
Galaxy Genomics Corp. is an American biotechnology company focused on providing the most advanced and specialized software to help companies from different sectors to develop a better future. We use advanced mathematical and computational deterministic algorithms to allow our users to create proteins, peptides, and enzymes accurately, achieve significant reductions in research cost and time. On average, it takes at least ten years for a new medicine to complete the journey from initial discovery to the marketplace, with clinical trials alone taking six to seven years on average. The average cost to research and develop each successful drug is estimated to be $2.6 billion. The development time is 3 to 5 years. We can reduce the development time to few months. we are in a starting phase
Featured metrics
we are in a starting phase
Selling details
Type of shares
This is some text inside of a div block.
Reason for selling
I am one of the 2 co-founders, I own 50% of the company. I wish to sell max 10% of my equity because I need some liquidity.
Preferred acquirer
Aspirations & growth opportunities
we are just contracting with a biotech company based in Europe and the potentials to growth are huge.
Business details
Business model
sell services about proteins/peptides/enzymes
1 (biotech/pharma/cosmetics companies and any business where proteins are involved)
many companies in the world perform research in the same direction, but no one can offer a deterministic model with exact results. All models available are probabilistic.
Operational details
Technology stack
ReactJS + MySQL
Marketing spend
0 (Linkedin - Direct contacts to research centers and bio-pharma companies)
Performance tracking tools
Financial details
Ownership structure
50/50 ownership between the 2 co-founders
Last month's revenue
Last month's profit
Financial records
Online reporting software/tools
TTM revenue
NA: we incorporated in october 2021
TTM net profit
NA: we incorporated in october 2021
Based in
Team members
Acquisition type
Desired valuation
open to offers
Message Owner
Message Broker